HK Stock MarketDetailed Quotes

02186 LUYE PHARMA

Watchlist
  • 2.360
  • -0.100-4.07%
Market Closed Dec 13 16:08 CST
8.88BMarket Cap10.54P/E (TTM)

About LUYE PHARMA Company

Luye Pharmaceutical Group Co., Ltd. (the “Company”, together with its subsidiaries, collectively, the “Group”) is committed to the development, production, promotion and sale of innovative drugs in the four largest and fastest growing treatment fields (i.e. tumors, central nervous system (“central nervous system”), cardiovascular system, and digestion and metabolism) in the People's Republic of China (“China”), the United States of America (“the United States”), Europe and other countries or regions. The Group's product portfolio includes more than 30 products, covering more than 80 countries and regions around the world, including large-scale pharmaceutical markets China, the United States, Europe and Japan, as well as rapidly developing emerging markets. As far as the Chinese market is concerned, the Group has established a huge national sales and distribution network. In the first half of 2024, its products will be sold to 31 provinces, autonomous regions and municipalities directly under the Central Government. The Group carries out sales, marketing and distribution work through about 1,000 sales and marketing personnel and a network of about 1,650 dealers across the country, which together enabled the Group to sell its products to more than 21,450 hospitals. As far as the global market is concerned, the Group's business covers 80 countries and regions, including the United States, European Union (“EU”) countries, Japan, the Association of Southeast Asian Nations (“ASEAN”), Latin America, the Gulf Cooperation Council (“GCC”) region and other emerging countries or regions. The Group also has strong sales partner relationships, with more than 50 partners worldwide. The Group's research and development (“R&D”) activities are comprised of four chemical platforms, namely long-acting and sustained-release technology, liposome and targeted drug delivery, transdermal drug delivery systems, and novel compounds. The Group has expanded its R&D capabilities to the biological field supported by the four cutting-edge platforms of Shandong Boan Biotechnology Co., Ltd. (“Boan Biology”), namely the whole-human antibody-transgenic mouse and bacteriophage display technology platform, the bispecific T-cell bridging system technology platform, the antibody-conjugated drug (“ADC”) technology platform and cell therapy platform. The Group balances clinical development risks by strategically allocating resources to develop proven compounds and novel drugs, biosimilars and proprietary formulations of innovative biopharmaceuticals. The Group believes that its R&D capabilities will become the Group's long-term competitiveness and the driving force for future growth and development. As of June 30, 2024, the Group's R&D team consists of 720 employees, including 66 doctorates and 351 master's degrees in medicine, pharmaceuticals and other related fields. As of June 30, 2024, the Group has obtained a total of 272 patents and 66 patents are in the application stage in China, and a total of 552 patents have been obtained overseas and 123 patents are in the application stage. The Group will continue to invest in products developed in the four strategic treatment fields of oncology, central nervous system, cardiovascular and metabolism. As of June 30, 2024, the Group has 27 products under development in China at various stages of development. The drugs under development include 18 types of tumor products, 5 types of central nervous system products, and 4 other products. In addition, the Group has 11 products under development in the US, Europe and Japan at various stages of development.

Company Profile

Symbol02186
Company NameLUYE PHARMA
ISINBMG570071099
Listing DateJul 9, 2014
Issue Price5.92
Shares Offered999.64M share(s)
FoundedJul 2, 2003
Registered AddressBermuda
Chairmandianbo liu
Secretarymeiyi li
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeClarendon House 2 Church Street Hamilton HM 11 Bermuda
Head Office and Principal Place of BusinessRoom 3207, Champion Tower, 3 Garden Road, Central, Hong Kong
Fiscal Year Ends12-31
Employees5234
MarketHong Kong motherboard
Phone(852)35230428
Fax(852)35240430
Emailluye@luye.cn
Business Luye Pharmaceutical Group Co., Ltd. is an investment holding company mainly engaged in the development, production, promotion and sale of pharmaceuticals. The company and its subsidiaries operate through four major divisions: Oncology Drugs Division, Cardiovascular Medicine Division, Digestive and Metabolic Drugs Division, and others. The company's main products include paclitaxel preparations for chemotherapy of cancer, injectable compounds for radiation therapy of solid tumors, traditional Chinese medicine for treating hyperlipidemia, acarbose capsules for the treatment of type 2 diabetes, and cabalatin transdermal patches for the treatment of Alzheimer's disease. The products are sold under brands such as Liposin, Ximena, Lipocam, Medona, and Bechy. The company is also engaged in providing contract research and program development through its subsidiaries. The company mainly operates in mainland China.

Company Executives

  • Name
  • Position
  • Salary
  • dianbo liu
  • CEOs, Executive Director, Executive Chairman
  • 4.18M
  • rongbing yang
  • Vice-chairman, Executive Director, Authorized Representative
  • 3.09M
  • huixian yuan
  • Executive Director
  • 1.46M
  • yuanyuan zhu
  • Executive Director, Authorized Representative
  • 1.50M
  • ruilin song
  • Non-executive Directors
  • 269.00K
  • dong lv
  • Non-executive Directors
  • --
  • huaqiao zhang
  • Independent Non-Executive Director, Remuneration Committee Members, Nomination Committee Members, Audit Committee Members
  • 269.00K
  • yulin lu
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Audit Committee Members
  • 269.00K
  • minjie liang
  • Independent Non-Executive Director, Chairman of the Audit Committee
  • 322.00K
  • sicong cai
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members
  • 269.00K
  • lian xia
  • Independent Non-Executive Director
  • 162.00K
  • yuanchong liu
  • Chief Financial Officer
  • --
  • li li
  • VP
  • --
  • meiyi li
  • Company Secretary
  • --
Trending HK Stocks
HK Tech and Internet Stocks HK Tech and Internet Stocks

Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data.